Jazz Pharma appoints Renee Gala as President & CEO, effective Aug 11, 2025; Cozadd remains Chair

Jazz Pharmaceuticals plc

Renee Gala, previously President & COO, becomes President & CEO effective August 11, 2025, and joins the Board.
Bruce Cozadd retires as CEO on Aug 11, transitions to advisor through Sep 12, then remains Chairperson.
Gala's base salary increases to $1.2M (from $900k); target bonus rises to 110% of salary (from 80%).
Gala receives a one-time promotion equity grant of ~$6.5M (33% RSUs, 67% PSUs) on top of $6M annual grant.
Severance enhanced: lump sum of 150% base salary (was 100%) and COBRA coverage extended to 18 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.